Ticker: FULC

Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Overview Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for genetically defined rare diseases. The company's key product candidate is pociredir, which is under clinical development for treating sickle ce...

Fulcrum Therapeutics, Inc. (NASDAQ: FULC) has recently reported its quarterly results for the period ending March 31, 2025. The company is focused on developing targeted therapies for genetically defined rare diseases, with its primary candidate being pociredir for sickle cell disease (SCD). Key ...